Back to search

University of British Columbia

Granzyme K : a novel contributor in cardiac allograft vasculopathy

Abstract

dc:description

Background - A major factor limiting survival for patients that have undergone cardiac transplantation is cardiac allograft vasculopathy (CAV). CAV is a fibroproliferative inflammatory form of vascular rejection mediated by immune cells and which is initiated upon damage to the graft endothelium and medial smooth muscle cells (SMC). Granzymes are a family of five serine proteases in humans. Granzymes have been shown to exert roles in cell death, endothelial dysfunction, inflammation and matrix remodeling. Granzyme K (GzmK) specifically can promote endothelial dysfunction and the production of inflammatory mediators IL-1β, IL-6, and monocyte chemotactic protein-1. As such, we hypothesized that GzmK contributes to CAV. Methods - An infrarenal aortic interposition graft was completed across a complete major histocompatibility complex (MHC)-mismatch with recipients being either wildtype or GzmK-KO mice. Allografts were then assessed for CAV severity and compared to human CAV samples. The effects of GzmK on human SMC were also assessed in vitro. Given that atherosclerosis shares similar underlying mechanisms to CAV, GzmK deposition was also characterized in atherosclerosis. Results - Human CAV samples demonstrated increased neointimal GzmK deposition as compared to unaffected native coronaries (p= 0.017). GzmK primarily localized to the medial and neointimal layers. Similar deposition patterns were observed in murine transplants. When the role of GzmK was examined, GzmK deficiency resulted in reduced CAV with less neointima formation (p=0.019) and less luminal obstruction (p<0.0163). GzmK deficiency also had significantly less cellular proliferation as measured by Ki67 (p=0.026) while apoptosis (as measured by cleaved caspase 3) was unaffected (p=0.711). In vitro, GzmK lacked cytotoxicity on SMC whereas it increased cellular proliferation by 30% (p=0.038). Immunofluorescence co-localized GzmK with macrophages and lymphocytes while GzmK deposition was also observed in GzmK-KO recipients indicating that it is potentially graft derived. Conclusion – GzmK contributes to CAV with GzmK potentially arising from recipient and graft derived sources. GzmK may serve as a novel therapeutic target in CAV

Degree

thesis:*
Name thesis:degree_name
Master of Science - MSc
Level thesis:degree_level
master's
Discipline thesis:degree_discipline
Experimental Medicine
Grantor dc:publisher
University of British Columbia
Year dc:date
2020

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Tauh, Keerit

Rights

dc:rights
Statement dc:rights
  • Attribution-NonCommercial-NoDerivatives 4.0 International
Language dc:language
eng

Identifiers

dc:identifier.*
Handle dc:identifier
http://hdl.handle.net/2429/75778

Chain of custody

source
Harvested from
University of British Columbia
Base URL
circle.library.ubc.ca/oai/request
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
related terms
citation

Tauh, Keerit. Granzyme K : a novel contributor in cardiac allograft vasculopathy. master's thesis, University of British Columbia, 2020. http://hdl.handle.net/2429/75778